Editorial Perspectives On Patient Recruitment
-
Funding Diversity Where It Starts — At The Site
11/3/2025
After crossing paths with retired family physician and researcher Dr. Bryce Palchick at two conferences, I learned about ACRO’s new Diversity & Inclusion Site Resource Grants Program — an effort funding community sites like Bryce’s to make trial diversity more than a buzzword by supporting real, grassroots engagement.
-
When Survival Comes First, Trials Come Last
8/1/2025
Infectious disease PI Dr. Claudia Martorell has long focused on recruiting underserved populations into clinical trials. But amid healthcare cuts, economic instability, and a retreat from DEI initiatives, she’s now watching access unravel. In this interview, Martorell shares what happens when survival takes priority over research — and why diversity in trials is once again at risk.
-
PI's CRAACO Model + AI = Rapid Enrollment
6/30/2025
At Dr. David Almeida’s clinical trial site in Erie, PA, he practices the CRAACO model exclusively, relying on the revenue he makes from conducting clinical trials for eye-related diseases. To minimize his costs and speed up trial enrollment, he uses a proprietary AI system that has given him an 85% screen-to-enroll ratio.
-
Takeda's Diversity Strategy Pays Off For Phase 3 Trial
3/12/2025
LaShell Robinson, head of global feasibility and trial equity at Takeda explains how the company’s Phase 3 trial for a psoriasis drug ended enrollment well before it’s goal and achieved some impressive diversity metrics.
-
The Scoop On SCOPE
2/7/2025
Chief Editor Dan Schell summarizes some of his favorite quotes and learnings from the 2025 SCOPE Summit. Spoiler alert … Not everything is about AI these days.
-
We're Looking At Patient Recruitment All Wrong
1/22/2025
Leanne Woehlke, a 30-year veteran of the clinical research industry, says our standard patient recruitment efforts are lacking one key element — a focus on the patient’s needs.
-
Let's Fix The Tax Burden On Clinical Trial Participants
12/10/2024
We all know that patient retention is lowered once a participant realizes the tax implications of being in a clinical trial. But taxes should be the last thing they have to worry about, so why can’t we get some changes made?
-
2024: Familiar Problems & Encouraging Progress
11/27/2024
For part 1 of my 2024 recap, I asked various industry experts what stood out to them this year regarding the clinical trials industry. They mentioned significant challenges related to site capacity, enrollment, workforce changes, and trial complexity, but they also seemed encouraged with some of the efforts and emerging solutions that will address these issues.
-
Not A Bad First Year
11/11/2024
Dan Schell, chief Editor or Clinical Leader, summarizes his first year in this role and highlights some of his key takeaways and lists some of the people who have helped him better understand the clinical trials ecosystem.
-
Key Takeaways From Clinical Trial Diversity Discussion
9/24/2024
During the Clinical Leader Live, The Diversity Mandate: Effective Strategies in Clinical Trials”, we discussed everything from the guidance, to diversity action plans, to the need for better data on race, ethnicity, and identity. In this article, we also share 25 questions audience members had regarding this hot topic.